Clinical Trial Update: A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN [Phase 4]

View source ↗

Summary

Phase 4 study evaluating adverse events within one day of TEGSEDI administration in adults with hereditary transthyretin amyloidosis with polyneuropathy; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin Amyloidosis with Polyneuropathy

Drugs mentioned

• TEGSEDI (inotersen)

Snippet

Sponsor: Akcea Therapeutics | Conditions: Hereditary Transthyretin Amyloidosis With Polyneuropthy | Phase 4 | Status: TERMINATED | Results posted: 2025-04-10